We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Treatment with Transforming Growth Factor Alpha Restores Motor Function after Stroke

By LabMedica International staff writers
Posted on 28 Jan 2010
Positive results from two studies conducted in rats suggest that the small protein transforming growth factor alpha (TGF-alpha) has the potential to restore motor function in stroke victims as long as four months after the event.

Investigators at the University of California, Irvine (USA) worked with a rat stroke model where the disease was induced through a middle cerebral artery occlusion (MCAO). More...
Treatment of the animals with TGF-alpha was either by direct delivery to the animals' brains (as described in the May 5, 2009, issue of the journal Neuroscience) or - mimicking a nasal spray - through the nose (as described in the January 11, 2010, online edition of the Journal of Stroke & Cerebrovascular Disease).

The earlier study found that direct injection of TGF-alpha into the brain restored nearly 90% of the paralyzed rats' motor function. Results of the latter study indicated that animals receiving the drug via the nose regained about 70% of motor function. Rats that did not receive treatment with TGF-alpha recovered only about 30% of motor function.

Examination of brain tissue from the paralyzed rats showed that TGF-alpha produced a massive proliferative response even when the growth factor was administered as late as four weeks after injury. The newly generated cells migrated preferentially along and ventral to the corpus callosum and external capsule to the site of the injury where many of them differentiated into several site-appropriate neuronal phenotypes in association with near complete (99%) behavioral recovery.

"No drugs exist that will help a stroke after a few days. If you have a stroke, you do not have many treatment options," said senior author Dr. James Fallon, professor of psychiatry and human behavior at the University of California, Irvine. "Now we have evidence there may be therapies that can repair damage to a significant degree long after the stroke. It's a completely unexpected and remarkable finding, and it is worth trying in humans."

Related Links:

University of California, Irvine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.